Investigational drug · Phase 2
SB17170
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "SB17170"
First trial start
2025
Jan 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SB17170", any sponsor or status.
Conditions studied
As listed on its trial records.
- IPF
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "SB17170" as an intervention, largest first.
SPARK BiopharmaIndustry
NCT05795192 · 64 participants · Start May 24, 2023 · Primary completion Feb 29, 2024
Drug: SB17170; Placebo · For: Safety Issues; Tolerability; Pharmacokinetics and 1 more
Sites: Seoul, South Korea
SPARK BiopharmaIndustry
NCT05522868 · 50 participants (planned) · Start Oct 17, 2022 · Primary completion Jun 30, 2027
Drug: SB17170 · For: Solid Tumor
Sites: Seoul, South Korea · 3 sites in all
SPARK BiopharmaIndustry
NCT06747923 · 32 participants · Start Jan 27, 2025 · Primary completion Jul 21, 2026
Drug: SB17170; Placebo · For: IPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
Sites: Goyang, South Korea; Gwangmyeong, South Korea; Seoul, South Korea · 5 sites in all
SPARK BiopharmaIndustry
NCT06846684 · 12 participants · Start Mar 27, 2025 · Primary completion Jun 10, 2025
Drug: SB17170; SB_MDZ · For: Drug Drug Interaction (DDI)
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IPF
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.